Gastrointestinal Diseases Applications
-
Microscope System for Molecular imaging of cancer
Longitudinal imaging of pancreatic cancer. Monitor in a minimally invasive manner both tissue morphology and fibrosis (fluorescein) and cathepsin activity (Prosense® 680). A very thin probe (S 650) was used to monitor the pancreas of the same mouse over 9 months. ...
By Mauna Kea Technologies based in Paris, FRANCE.
-
Microbiome Therapeutics for Patients and Physicians
Seres’ microbiome therapeutics represent a transformative new approach to ...
By Seres Therapeutics, Inc. based in Cambridge, MASSACHUSETTS (USA).
-
Bioinformatics software solutions for metagenomics sector
Metagenomics is the study of all microbial genomes present in an environment, from the bottom of the sea to inside our own bodies. If you have shotgun NGS sequencing data, Partek provides powerful, easy-to-use analysis tools to characterize microbial ...
By Partek Incorporated based in Chesterfield, MISSOURI (USA).
-
Probiotics: Pharmaceutical-Quality Innovative Solutions
The use of probiotics is a very promising alternative for the prevention and/or treatment of multiple health issues, in both humans and animals. By modifying the composition of the microbiota with probiotics, we may help to mitigate and solve upper respiratory, genitourinary or gastrointestinal tracts and periodontal infections, as well as dysbiosis issues related to fertility, premature births, dermatology, autoimmune diseases, and many more. The key is to choose the appropriate strain and dosage for each ...
By Zinereo Pharma based in Pontevedra, SPAIN.
-
Secca Therapy - Bowel Incontinence
An estimated 20 million people in the U.S. struggle with bowel incontinence, and an estimated 80% suffer in silence. Secca therapy is a safe, effective, minimally invasive procedure to treat bowel incontinence. Secca therapy is an innovative treatment option for patients with BCD, who have not responded to conservative treatments and would like to avoid invasive surgery or implants. ...
By Restech based in Houston, TEXAS (USA).
-
Microbiome Therapeutics for Clinical Trials
Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of ...
By Finch Therapeutics Group, Inc. based in Somerville, MASSACHUSETTS (USA).
-
Exhaled Breath and Gas Monitoring Instruments for Gastroenterology industry
We have designed a range of breath monitors that are non invasive and low cost to aid in the detection of gastrointestinal disorders such as diagnose lactose intolerance, fructose intolerance, glucose intolerance and many others. The breath tests are easy to perform and multiple patients can be tested for gastrointestinal disorders in one session with our breath ...
By Bedfont Scientific Limited based in Kent, UNITED KINGDOM.
-
Microbiota Based Product for Physician-Sponsored Studies
With the microbiota-based MRT™ drug platform, Rebiotix Inc., a Ferring Company, is on the forefront of a new era of medical ...
By Rebiotix Inc., a Ferring Company based in Roseville, MINNESOTA (USA).
-
Klarity - Built Therapeutic Platform Technologies for Gastrointestinal Disease
A defective gastrointestinal (GI) barrier is associated with multiple conditions of high unmet need, including inflammatory bowel disease, chemotherapy-induced gut injury, food allergies, and celiac disease. We are advancing novel, oral, non-immunosuppressive therapeutics to improve GI barrier function. Our multi-targeted approach involves improving epithelial cell homeostasis, restoring appropriate immune responses, and repairing secretory cell ...
By Kallyope Inc. based in New York City, NEW YORK (USA).
-
Medical diagnostics solutions for inflammatory bowel disease sector
Inflammatory bowel disease (IBD), largely comprising the two conditions, Crohn’s Disease and Ulcerative Colitis, is now emerging as a global health problem. It now affects about 6 million people in Europe and US, comprising up to 620,000 in the UK (IBD Standards UK, 2013 Update). The symptoms of diarrhoea, abdominal pain and bloody stool substantially affect the quality of life of sufferers, and complications can be life threatening. IBD is also strongly associated with colorectal cancer development risk. ...
By DiagNodus Ltd. based in Cambridge, UNITED KINGDOM.
-
Peri-anal Fistula
Stempeucel® can reduce inflammation, which allows the tissues around the fistula tract to ...
By Stempeutics Research Pvt. Ltd. based in Bangalore, INDIA.
-
Groundbreaking Proprietary Investigational Drug for Crohn`s disease
Effecting an estimated one million Americans, Crohn's disease can be highly debilitating and remains a serious burden for both patients and healthcare systems. ...
By RedHill Biopharma Ltd. based in Tel-Aviv, ISRAEL.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you